SprangC. and WinkleB., “Informed Consent in Theory and Practice: Legal and Medical Perspective on the Informed Consent Doctrine and a Proposed Reconceptualization,”Critical Care Medicine, 17 (1989): 1346–54; and ShugrueR. and LinstrombergK., “The Practitioner's Guide to Informed Consent,”Defense Law Journal, 41 (1992): 73–125.
2.
SchneyerT., “Informed Consent and the Danger of Bias in the Formation of Medical Disclosure Practices,”Wisconsin Law Review, 1976 (1976): 124–70; and Shugrue and Linstromberg, supra note 1, at 82.
3.
Schneyer, supra note 2, at 147–48.
4.
Sprung and Winkle, supra note 1, at 1346; BeecherH., “Consent in Clinical Experimentation–Myth and Reality,”Journal of the American Medical Association, 195 (1966): 34–35; LaforetE., “The Fiction of Informed Consent,”Journal of the American Medical Association, 235 (1976): 1579–85; and WettsteinR., “Tardive Dyskinesia and Malpractice,”Behavioral Sciences and the Law, 1 (1983): 85–105.
5.
MaldonadoJ., “Strict Liability and Informed Consent: “Don't Say I Didn't Tell You So!”,”Akron Law Review, 9 (1976): 609–28.
6.
Note, “Malpractice: Toward a Viable Disclosure Standard for Informed Consent,”Oklahoma Law Review, 32(1979): 868–90.
7.
MerzJ. and FischhoffB., “Informed Consent Does Not Mean Rational Consent: Cognitive Limitations of Decision-Making,”Journal of Legal Medicine, 11 (1990): 321–50; and Note, “Informed Consent–A Proposed Standard for Medical Disclosure,”New York University Law Review, 48 (1973): 548–63.
8.
Shugrue and Linstromberg, supra note 1, at 79–80; and WaltzJ. and ScheunemanT., “Informed Consent to Therapy,”Northwestern University Law Review, 64 (1970): 628–50.
9.
MerzJ., “On a Decision-Making Paradigm of Medical Informed Consent,”Journal of Legal Medicine, 14 (1993): 231–64.
10.
TennenhouseD., “Symposium on Medicolegal Problems in Ophthalmology: Common Misconceptions,”Ophthalmology (Rochester), 86 (1979): 1225–27.
11.
Shugrue and Linstromberg, supra note 1, at 77.
12.
RosoffA., Informed Consent: A Guide for Health-Care Practitioners (Rockville: Aspen, 1981), at 33.
13.
Shugrue and Linstromberg, supra note 1, at 81.
14.
Merz and Fischhoff, supra note 7, at 321.
15.
Id. at 322; and Salgo v. Leland Stanford, Jr., University Board of Trustees, 154 Cal. App. 2d 560; 317 P.2d 170 (1957).
16.
Shugrue and Linstromberg, supra note 1, at 123; and American College of Legal Medicine, Legal Medicine: Legal Dynamics of Medical Encounters (St. Louis: Mosby Year Book, 2nd ed., 1991), at 222.
17.
President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, Making Health-Care Decisions: The Ethical and Legal Implications of Informed Consent in the Patient-Practitioner Relationship. Informed Consent as Active, Shared Decision-Making (Washington, D.C.: U.S. Government Printing Office, Vol. 1, 1982), at 17; Rosoff, supra note 12, at 41; Shugrue and Linstromberg, supra note 1, at 97; and “Nature and Degree of Risk as Affecting Duty to Inform,”American Jurisprudence 2d, 61 (1981): § 190.
18.
Cooper v. Roberts, 220 Pa. Super. 260, 286 A.2d 647, (1971).
19.
WaltzJ.R. and ScheunemanT.W., “Informed Consent to Therapy,”Northwestern University Law Review, 64 (1970): 630; and President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, Making Health Care Decisions: The Ethical and Legal Implications of Informed Consent in the Patient-Practitioner Relationship. The Law of Informed Consent (Washington, D.C.: U.S. Government Printing Office, Vol. 3, 1982), at 193.
20.
Shugrue and Linstromberg, supra note 1; Merz and Fischhoff, supra note 15, at 329; and American Jurisprudence 2d, supra note 17, at § 188.
21.
American Jurisprudence 2d, supra note 17, at § 188; and MeyerM.J., “Patients” Duties,”Journal of Medicine and Philosophy, 17 (1992): 541–55.
22.
GaylinW., Doing Good: The Limits of Benevolence (New York: Pantheon, 1978), at 82–93; and President's Commission, supra note 17, at 34.
23.
GildW., “Informed Consent: A Review,”Anesthesia and Analgesia, 68 (1989): at 652.
24.
KeetonW.DobbsD.KeetonR. and OwenD., Prosser and Keeton on the Law of Torts (St. Paul: West Publishing, 5th ed., 1984), at § 32.
25.
MyersM.J., “Informed Consent in Medical Malpractice,”California Law Review, 55 (1967): at 1405; and Shugrue and Linstromberg, supra note 1, at 95.
26.
Shugrue and Linstromberg, supra note 1, at 95; and KatzJ., “Informed Consent–A Fairy Tale? Law's Vision,”University of Pittsburgh Law Review, 39 (1977): at 157.
27.
Rosoff, supra note 12, at 55.
28.
Shugrue and Linstromberg, supra note 1, at 95; American Law Reports 3d, 88 (1978): at 1036; and Myers, supra note 25, at 1404.
29.
Cobbs v. Grant, 8 Cal. 3d 229, 502 P.2d 1 (1972); and American Law Reports 3d, supra note 28, at 1035.
30.
BursztainH.HammR.M.GutheilT.S. and BrodskyA., “The Decision-Analytic Approach to Medical Malpractice Law: Formal Proposals and Informal Syntheses,”Medical Decision Making, 4 (1984): 402–14; and Myers, supra note 25, at 1404.
31.
Merz, supra note 9, at 240.
32.
Bursztain, supra note 30.
33.
Note, supra note 6.
34.
Id. at 877.
35.
Id.
36.
Schneyer, supra note 2, at 143.
37.
Cooper v. Roberts, supra note 18.
38.
Canterbury v. Spence, 464 F.2d 772, 787 (D.C. Cir. 1972), cert. denied, 409 U.S. 1064 (1972), 93 S. Ct. 560, 34 L.Ed.2d 518 (1972).
39.
Cooper v. Roberts, supra note 18, at 650.
40.
Canterbury v. Spence, supra note 38, at 786–87.
41.
Merz, supra note 9, at 251; and Nishi v. Hartwell, 52 Haw. 188, 473 P.2d 116 (1970).
42.
CapronA.M., “Informed Consent in Catastrophic Disease Research and Treatment,”University of Pennsylvania Law Review, 123 (1974): at 408.
43.
EpsteinR., “Medical Malpractice: The Case for Contract,”American Bar Foundation Research Journal, 35 (1976): at 121.
44.
McPherson v. Ellis, N.C. 287, S.E.2d 892 (1982).
45.
Cobbs v. Grant, 8 Cal. 3d 229, 502, P.2d 1 (1972).
Merz and Fischhoff, supra note 7, at 333; Schneyer, supra note 2, at 143; and Canterbury v. Spence, supra note 38, at 788.
49.
MazurD.J., “Judicial and Legislative Viewpoints on Physician Misestimation of Patient Dysutilities: A Problem for Decision Analysts,”Medical Decision Making, 10 (1990): 172–80; Merz, supra note 9, at 244; and RozovskyF.A., Consent to Treatment: A Practical Guide (Boston: Little, Brown, 1984), at 54.
ZeBarth v. Swedish Hospital Medical Center, 81 Wash. 2d 12, 499 P.2d 1 (1972).
67.
Hartke v. McKelway, 707 F.2d 1544 (D.C. Cir. 1983), cert. denied, 464 U.S. 983, 104 S. Ct. 425, 78 L.Ed. 360 (1983).
68.
Canterbury v. Spence, supra note 38, at 788.
69.
Hondroulis v. Schumacher, 546 So. 2d 466 (La. 1989).
70.
Sprung and Winick, supra note 1, at 1348.
71.
KatzJ., The Silent World of Doctor and Patient (New York: The Free Press, 1984), at 82.
72.
President's Commission, supra note 17, at 23.
73.
Katz, supra note 71, at 82.
74.
President's Commission, supra note 19; MazurrD.J., “Why the Goals of Informed Consent are not Realized: Treatise on Informed Consent for the Primary Care Physician,”Journal of General Internal Medicine, 3 (1988): at 371; Merz and Fischhoff, supra note 7, at 330; and PegalisS.E. and WachsmanH.F., American Law of Medical Malpractice 2d (Deerfield, Illinois: Clark Boardman Callaghan, 1992), at 196.
75.
Scott v. Bradford, 606 P.2d 554 (Okla. 1979).
76.
Epstein, supra note 43, at 124.
77.
Schneyer, supra note 2, at 146.
78.
McKinney v. Nash, 174 Cal. 642, 12 Cal. App. 3d 428 (1976).
79.
Merz, supra note 9, at 258.
80.
WoernerM.G., “The Prevalence of Tardive Dyskinesia,”Journal of Clinical Psychopharmacology, 11 (1991): 34–42; JesteD.V. and CaligiuriM.P., “Tardive Dyskinesia,”Schizophrenia Bulletin, 19 (1993): 303–12; and CavallaroR., “Tardive Dyskinesia Outcomes: Clinical and Pharmacologic Correlations of Remission and Persistence,”Neuropsychopharmacology, 8 (1993): 233–39.
81.
GlazerW.M., “Predicting the Long-Term Risk of Tardive Dyskinesia in Outpatients Maintained on Neuroleptic Medications,”Journal of Clinical Psychiatry, 54 (1993): 133–39; MorgensternH. and GlazerW.M., “Identifying Risk Factors for Tardive Dyskinesia Among Long-Term Outpatients Maintained with Neuroleptic Medications,”Archives of General Psychiatry, 50 (1993): 723–33; GuyW., “The Prevalence of Abnormal Involuntary Movements Among Chronic Schizophrenics,”International Clinical Psychopharmacology, 1 (1986): 136–44; KaneJ.M., “The Prevalence of Tardive Dyskinesia,”Psychopharmacology Bulletin, 21 (1985): 136–39; KaneJ.M. and SmithJ.M., “Tardive Dyskinesia: Prevalence and Risk Factors, 1959 to 1979,”Archives of General Psychiatry, 39 (1982): 473–81; and YassaR. and JesteD.V., “Gender Differences in Tardive Dyskinesia: A Critical Review of the Literature,”Schizophrenia Bulletin, 18 (1992): 701–15.
82.
JesteD.V. and WyattR.J., “Changing Epidemiology of Tardive Dyskinesia: An Overview,”American Journal of Psychiatry, 138 (1981): 297–309; KaneJ.M., “Tardive Dyskinesia: Prevalence, Incidence, and Risk Factors,”Journal of Clinical Psychopharmacology, 8 (1988): 528–68; and Kane and Smith, supra note 81.
83.
Woerner, supra note 80.
84.
Jeste and Caligiuri, supra note 80; and Woerner, supra note 80.
85.
Cavallaro, supra note 80.
86.
Jeste and Caligiuri, supra note 80; and GlazerW., “Race and Tardive Dyskinesia Among Outpatients at a CMHC,”Hospital and Community Psychiatry, 45 (1994): 38–42.
87.
EddyD.M., “Variations in Physician Practice: The Role of Uncertainty,”Health Affairs, 3 (1984): 74–89.
88.
CebulR.D., “A Look at the Chief Complaints” Revisited: Current Obstacles and Opportunities for Decision Analysis,”Medical Decision Making, 4 (1984): 272–83.
89.
Eddy, supra note 87.
90.
KatzJ., “Why Doctors Don't Disclose Uncertainty,”Hastings Center Report, 14 (1984): 35–44; GutheilT.G., “Malpractice Prevention Through the Sharing of Uncertainty: Informed Consent and the Therapeutic Alliance,”New England Journal of Medicine, 311 (1984): 49–51; and CarmiA., “Medical Decisions Under Uncertainty,”Medicine and the Law, 12 (1993): 277–81.
91.
MazurD.J., “Informed Consent: Court Viewpoints and Medical Decision Making,”Medical Decision Making, 6 (1986): 224–30.
92.
Cobbs v. Grant, supra note 29, at 11.
93.
Gutheil, supra note 90.
94.
RoginskyM.S. and WassermanS., “Informed Consent: Past, Present, and Future?,”New York State Journal of Medicine, Nov. (1979): 1918–20.
95.
Harbeson v. Parke-Davis, Inc., 746 F.2d 517 (9th Cir. 1984).
96.
BrodyH., “Transparency: Informed Consent in Primary Care,”Hastings Center Report, 19 (1989): 5–9; and PlautE., “The Ethics of Informed Consent: An Overview,”Psychiatric Journal of the University of Ottawa, 14 (1989): 435–38.
97.
Rosoff, supra note 12, at 47.
98.
Nisenholtz v. Mount Sinai Hospital, 126 N.Y. Misc. 2d 658, 662, 483 N.Y.S.2d 568 (1984).
99.
GambrillE., Critical Thinking in Clinical Practice: Improving the Accuracy of Judgments and Decisions About Clients (San Francisco: Jossey-Bass, 1990), at 9 and ch. 9.
100.
AppelbaumP.LidzC. and MeiselA., Informed Consent: Legal Theory and Clinical Practice (New York: Oxford, 1987), at 145.
101.
LidzC.AppelbaumP. and MeiselA., “Two Models of Implementing Informed Consent,”Archives of Internal Medicine, 148 (1988): 1385–89.
102.
HolzerJ., “A New Approach to Informed Consent Can Reduce Claims,”Pediatric Annals, 20 (1991): 64–68.
103.
GreenJ., “Minimizing Malpractice Risks by Role Clarification: The Confusing Transition from Tort to Contract,”Annals of Internal Medicine, 109 (1988): 234–41.
104.
VagoS., Law and Society (Englewood Cliffs: Prentice-Hall, 1994), at 8.
105.
Appelbaum, supra note 100, at 145; President's Commission, supra note 19, at 30–31; and PellegrinoE., “Toward a Reconstruction of Medical Morality: The Primacy of the Act of Profession and the Fact of Illness,”Journal of Medicine and Philosophy, 4 (1979): 32–56.
106.
Maldonado, supra note 5.
107.
Katz, supra note 71, at 82; and Katz, supra note 26, at 172–73.
108.
American College of Physicians, “American College of Physicians Ethics Manual,”Annals of Internal Medicine, 101 (1984): 129–36.
109.
Lidz, supra note 101.
110.
Brody, supra note 96.
111.
Green, supra note 103.
112.
Gutheil, supra note 90.
113.
DewanM.J., “Adding Medications to Ongoing Psychotherapy: Indications and Pitfalls,”American Journal of Psychotherapy, 46 (1992): 102–10.
114.
PiesR., Letter: Response to “This Prescription May be Hazardous to Your Health: Who is Accountable to the Patient?,”Journal of Clinical Psychopharmacology, 13 (1993): 457.
115.
Rosoff, supra note 12, at 46.
116.
Katz, supra note 26, at 160.
117.
Epstein, supra note 43, at 127.
118.
Id. at 120–21.
119.
American College of Legal Medicine, supra note 16, at 221.
120.
Brody, supra note 96.
121.
305 N.W.2d 589 (Minn. 1981)
122.
544 So.2d 567 (La. App. 1989).
123.
Katz, supra note 26, at 166; and Canterbury v. Spence, supra note 38, n. 84 at 787.
124.
Green, supra note 103; Appelbaum, supra note 100; and Meyer, supra note 21.
125.
Gutheil, supra note 90; and Wilkinson v. Vesey, 110 R.I. 606, 295 A.2d 676 (1972).
126.
JonesC., “Autonomy and Informed Consent in Medical Decision-Making: Toward a New Self-Fulfilling Prophecy,”Washington and Lee Law Review, 47 (1990): 379–430.